Depressive, Bipolar and related disorders Flashcards

1
Q

withdrawal and discontinuation syndrome with antidepressants

A
  • physical symptoms (dizziness, diarrhea, insomnia)
  • psychological symptoms (anxiety, agitaiton, confusion)
  • titrate dose to prevent this
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

when does bipolar disorder develop

A
  • late teens or early adulthood
  • moslty before 25
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what should be monitored when taking SSRIs

A
  • thyroid function
  • side effects
  • therapuetic effects
  • watch for suicideal thoughts, hypomania, disinhibition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what needs to happen to be diagnosed with disorder

A
  • affects daily activities and QOL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what needs to be monitored when on lithium

A
  • lithium levels in the blood (0.8-1.2)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the leading helath problem of 21st centery

A
  • depressive disorder
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is prefrontal cortex responsible for (neuroanatomical)

A

congnition
- decision making

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is it called when major depressive episode and dysthymic overlap

A

double depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what do you monitor for when on carbamazepine

A
  • agranulocytosis
  • SJS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what do SSRIs do:

A
  • increase serotonergic activity
  • decrease action of presynaptic reuptake pump
  • allows neurotransmitters to stay in synapse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what diagnostics for persisitant depressive disorder

A
  • 2 or more symptoms for a year
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what criteria is needed to be diagnosed with MDD

A
  • 5 or more symptoms for 2 week span
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Volproates (anticonvulsants) monitoring

A
  • thrombocytopenia
  • extensive hepatic excretion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TCAs monitoring:

A
  • cardiac screening
  • serum potassium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TCAs MOA

A

block reuptake of serotonin and norepineprhine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

SNRIs treat depression by:

A
  • inhibiting reuptakes of serotonin and norepineprhine
  • increased stimulation of post-synaptic receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

side effects of TCAs

A
  • orthostaic hypotension
  • diaphoresis
  • sedation
  • cardiac toxicity
  • seizures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

serotonin modulators side effects

A
  • nausea
  • fatigue
  • dry mouth
  • constipation
  • weakness
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

serotonin modulators MOA

A
  • impacts serotonin, modulate one or more serotonin receptors and inhibit reuptake of serotonin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

S/E of SNRIs

A
  • nausea
  • dizziness
  • diaphoresis -
  • increased BP/HR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

S/E of lithium carbonate

A
  • tremor, polyuria, polydispsia, weight gain, diarrhea
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

risk factors

A
  • prior episodes
  • family history
  • lack social support
  • stress
  • economic difficulties
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

remission

A
  • minimal to no symptoms for more than 2 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

relapse

A
  • a return to fully symptomatic state during remission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

recurrence

A
  • appearance of new episode during recovery (not same as before)
26
Q

recovery

A
  • extended period of remission 6-12 months or more
27
Q

psychotherapuetic apporaches

A
  • CBT - bring in positive
  • interpersoanl psychotherapy (imporve social)
28
Q

psychosocial factors

A
  • cognitive
  • interpersonal
  • learned helplessness
  • attachment
29
Q

protective factors

A
  • low risk family history
  • engagment
  • resilience
30
Q

neurotranmistter affetcing depression

A
  • low levels of serotinin
  • low levels of nor-epinephrine and dopmaine
31
Q

neuroanatomical

A
  • low activity in dorsolateral prefrontal cortex and high limbic system
32
Q

mood stabilizer treatment

A
  • used to treat symptoms of mania
33
Q

mood disorders

A
  • bipolar
  • depression
34
Q

monitoring of SNRIs

A
  • check baseline BP/HR
  • height and weight in kids
35
Q

MAOIs MAO

A
  • block monoamine oxidase in synaptic cleft
  • not first or second line treatment
36
Q

major depression is considered:

A
  • persistant and reaccuring
37
Q

lithium carbonate (mood stabilizer) MOA

A
  • lithium reduces excitatory (dopamine and glutamate) and increases inhibitory (GABA) neurotransmission
38
Q

if SSRIs dont work then what?

A
  • use SNRIs
39
Q

hormonal disturbances in depression

A
  • hypothyroidsim
40
Q

goals for use of mood stabilizers

A
  • rapid relief of mania
  • prevent reaccurnece
  • imporve functioning and QOL
41
Q

ECT treatment

A
  • for clients who do not respond to medications
42
Q

dysthymic disorder

A
  • mild, chronic form of MDD
  • eating, sleeping are effected
  • low energy
  • cant make decisions
43
Q

DSM-5 diagnostic for hypomania episodes

A
  • abnormal behvaiors, persistently elevated, irritbale for 4 days
  • less severe than full mania on daily functioning
44
Q

DSM-5 criteria for manic episodes

A
  • elevated, expansive, irritable mood, high energy lasting a week
  • 3 or more symptoms
  • elevated form normal behaviors
45
Q

cytothymia contains:

A
  • dysthymia and hypomania
46
Q

common treatment options for major depression

A
  • psychotherapuetic approaches
  • psychopharmacologic approaches
  • electroconvulsive therapy
47
Q

cognitive theory

A
  • negative veiw of self
  • stressors
48
Q

catatonic sympotms

A
  • lack of movement, stoned face, non-responsive to stimuli
49
Q

carbamazepine (anticonvulsant) S/E

A
  • dizziness,
  • drowsiness
  • ataxia
  • nausea, vomiting
50
Q

Bipolar II criteria

A
  • starts with major depressive episode
  • has hypomania episodes
51
Q

bipolar I disorder

A
  • combination of full manic episodes and depressive disorder
  • more severe mania episodes
  • mania starts first
  • depressive episodes usually occur
52
Q

bipolar disorder

A
  • brain disorder causing shifts in mood, energy, activity levels, and ability to carry out daily tasks
53
Q

biological fatcors of depression

A
  • neurotransmitter
  • homronal disturbances
    neuroanatomical
54
Q

atypical antidepressants (buproprion) MOA

A
  • change elvels of neurotransmitters (dopamine, serotonin, norepinephrine)
  • effecting chnages in brain chemisrty and communication in brain nerve cell
55
Q

atypical antidepressant monitoring and side effects

A
  • weight and BP/HR
  • dry mouth, nausea, dizziness, anxiety, seizure risk
56
Q

antidepressants

A
  • 1st generation (old)
  • 2nd generation (new)
57
Q

anticonvulsants S/E

A
  • nausea, vomiting
  • headache
  • dizziness
  • increased appetite
58
Q

anticonvulsants (mood stabilizers) MOA

A
  • enhances GABA and stabilization fo sodium channels/prevention of neuronal firing
59
Q

anhedonia

A
  • negative symptoms with lack of pleasure
60
Q

additonal lithium monitoring

A
  • BUN, Cr, thyroid hormones and CBC
  • kidney damage
  • dry skin, constipation
61
Q

A/E of MAOIs

A
  • dizziness, fatigue
  • serotonin syndrome
  • hypertensive crisis
62
Q

2nd generation first line of choice

A
  • SSRIs